<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="669">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>18/10/2005</approvaldate>
  <actrnumber>ACTRN12605000657628</actrnumber>
  <trial_identification>
    <studytitle>A Multi-Centre, Open label Study to Investigate the Recovery of Interferon-b Efficacy in Relapsing-Remitting Multiple Sclerosis Patients with Neutralising IFN-b Antibodies and Reduced Bioavailability.</studytitle>
    <scientifictitle>A Multi-Centre, Open label Study to Investigate the Recovery of Interferon-b Efficacy in Relapsing-Remitting Multiple Sclerosis Patients with Neutralising IFN-b Antibodies and Reduced Bioavailability.</scientifictitle>
    <utrn />
    <trialacronym>RENeu</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsing-remitting Multiple Sclerosis</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Multiple sclerosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects will receive methylprednisolone 500mg oral daily for 3 consecutive days every month followed by AVONEX 30mcg IM weekly once the subject reverts to neutralising antibody negative status.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Return of bioavailability of AVONEXÂ® (Interferon b-1a) as measured by induction of MxA mRNA.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effects and safety of a washout period with monthly methylprednisolone followed by challenge with AVONEX® on: Proportion of patients becoming neutralising antibody negative.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients relapse free.</outcome>
      <timepoint>At 6, 12, 18 and 24 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total relapses</outcome>
      <timepoint>At 27 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with increase in Expanded Disability Status Scale (EDSS).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brain atrophy (BPF) measured on MRI</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative number of new or enlarging T2 lesions; T2 lesions volume; T1 lesions volume.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number and volume of enhancing lesions.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life assessment as measured on visual analogue scale (VAS).</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of relapsing-remitting multiple sclerosis; treated with interferon-b; EDSS below 6.0; test positive for NABs (at least 20 via CPE assay or at least 100 via MxA protein assay) on two consecutive tests at least 3 months apart; reduced bioavailability as measured by MxA mRNA/GAPDH.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>12/02/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen Idec Australia Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Biogen Idec Australia Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients taking beta interferon therapy for multiple sclerosis may develop antibodies to the therapy, called neutralising antibodies.  These antibodies can block the action of interferon, reducing its bio-availability for use in the body, thereby reducing its effectiveness as a treatment.  This study explores one possible way of reducing the levels of neutralising antibodies in the system by suspending interferon treatment, treating the patient with methylprednisolone to reduce the antibody levels, then restarting interferon therapy by giving AVONEX injections once weekly, and testing to see if the bio-availability or 'effectiveness' of the interferon therapy is restored.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Department of Neurology, Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dept. of Neurosciences, Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Department of Neurosciences, St Vincent's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dept of Neurology, Launceston General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dept of Neurology, Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Aaron Tabensky</name>
      <address>Biogen Idec Australia Pty Ltd
PO Box 380
North Ryde BC NSW 1670</address>
      <phone>+61 414297954</phone>
      <fax />
      <email>Aaron.Tabensky@biogenidec.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Aaron Tabensky</name>
      <address>Biogen Idec Australia Pty Ltd
PO Box 380
North Ryde BC NSW 1670</address>
      <phone>+61 414297954</phone>
      <fax />
      <email>Aaron.Tabensky@biogenidec.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>